1. Home
  2. INCY vs WSM Comparison

INCY vs WSM Comparison

Compare INCY & WSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Incyte Corp.

INCY

Incyte Corp.

N/A

Current Price

$120.67

Market Cap

23.7B

Sector

Health Care

ML Signal

N/A

Logo Williams-Sonoma Inc. (DE)

WSM

Williams-Sonoma Inc. (DE)

N/A

Current Price

$252.90

Market Cap

26.2B

ML Signal

N/A

Company Overview

Basic Information
Metric
INCY
WSM
Founded
1991
1956
Country
United States
United States
Employees
2844
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Home Furnishings
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
23.7B
26.2B
IPO Year
1994
1995

Fundamental Metrics

Financial Performance
Metric
INCY
WSM
Price
$120.67
$252.90
Analyst Decision
Buy
Buy
Analyst Count
28
23
Target Price
$130.63
★ $248.40
AVG Volume (30 Days)
★ 1.8M
839.5K
Earning Date
10-29-2026
11-18-2026
Dividend Yield
N/A
★ 1.17%
EPS Growth
★ 4173.33
0.57
EPS
0.50
★ 4.77
Revenue
$3,394,635,000.00
★ $7,806,816,000.00
Revenue This Year
$18.06
$6.18
Revenue Next Year
$3.30
$5.04
P/E Ratio
$79.26
★ $54.51
Revenue Growth
★ 13.67
1.24
52 Week Low
$89.25
$165.51
52 Week High
$132.60
$261.11

Technical Indicators

Market Signals
Indicator
INCY
WSM
Relative Strength Index (RSI) 56.42 56.91
Support Level $115.77 $216.31
Resistance Level $130.53 $258.00
Average True Range (ATR) 3.63 7.01
MACD 0.95 0.07
Stochastic Oscillator 79.39 55.72

Price Performance

Historical Comparison
INCY
WSM

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

About WSM Williams-Sonoma Inc. (DE)

With a retail and direct-to-consumer presence, Williams-Sonoma is a player in the nearly $300 billion domestic home category and $450 billion international home market, focused on expanding its exposure in the B2B ($80 billion total addressable market), marketplace, and franchise areas. Namesake Williams-Sonoma (153 stores) offers high-end cooking essentials, while Pottery Barn (181) provides casual home accessories. West Elm (117) is an emerging concept for young professionals, and Rejuvenation (13) offers lighting and house parts. Brand extensions include Pottery Barn Kids and Pottery Barn Teen (43) as well as Mark & Graham and GreenRow. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.

Share on Social Networks: